A novel Q3034R BRCA2 germline mutation identified in a fallopian tube cancer patient

Cancer Lett. 2003 Mar 10;191(2):211-4. doi: 10.1016/s0304-3835(02)00632-8.

Abstract

Fallopian tube cancer (FTC) accounts for 0.1-0.5% of all gynaecological malignancies, so that very few studies have demonstrated a significant linkage between this cancer type and BRCA1/BRCA2 mutations. We report the identification of a novel germline mutation (Q3034R) in BRCA2 gene in a 41-year-old patient. The nucleotide change (CAG > CGG) abolishes a DdeI restriction site, making genotype identification rapid and inexpensive. Our findings support the hypothesis that the primary FTC should be considered, at least in a subset of patients, as a BRCA2-associated tumor. Genetic counselling could result, in these cases, in early diagnosis of genetically predisposed individuals.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Deoxyribonucleases, Type II Site-Specific / metabolism
  • Fallopian Tube Neoplasms / genetics*
  • Fallopian Tube Neoplasms / pathology
  • Female
  • Genes, BRCA2*
  • Genetic Predisposition to Disease*
  • Germ-Line Mutation*
  • Humans
  • Polymerase Chain Reaction
  • Polymorphism, Single-Stranded Conformational
  • Prognosis

Substances

  • endodeoxyribonuclease DdeI
  • Deoxyribonucleases, Type II Site-Specific